Search

This document presents an update of the information and analyses on the Atlantic Salmon in Quebec gathered since the first review conducted in 2010, and is intended to support the reassessment of the status of the Atlantic Salmon (Salmo salar) by the Committee on the Status of Endangered Wildlife in Canada (COSEWIC). The information presented includes life history characteristics, habitat description, population abundance and threats to the species. A review of the data shows that the biological characteristics of the Atlantic Salmon and its freshwater habitats vary greatly among populations. Demographic trends also show high variability between populations. Although declines in salmon abundance were recorded in several rivers during the 1980s and 1990s, abundance levels have remained relatively stable over the past 20 years. In other rivers, abundance levels were fairly stable throughout the time series beginning in 1984. A few rivers remain in slow decline. However, no population appears to have become extinct, and the species' range has remained largely unchanged over time. The pressure exerted by various types of fishing, which is relatively well controlled and documented, has continued to decrease. Several other threats whose impacts are less well understood have a combined effect on Atlantic Salmon populations. [ABSTRACT FROM AUTHOR]

Competing Interests: None disclosed.

Myelodysplasia cutis is a relatively new described entity that is characterized by cutaneous plaques and nodules representing dermal infiltration of myeloid immature non-blastic cells. It can be related to myelodysplastic syndromes or myeloproliferative disorders. It has distinct clinical and histopathological features in comparison with leukemia cutis. We report an unusual case of late myelodysplasia cutis in a male patient with essential thrombocythemia. It is only the second case reported to be related to this myeloproliferative disorder., Competing Interests: Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article., (© The Author(s) 2022.)

Cutaneous larva migrans (CLM) is a zoonotic helminthiasis frequently imported to Canada by travellers to beach destinations in the tropics. The preferred treatment is oral ivermectin. We present a case of CLM acquired within the province of Quebec, a first in our provincial health records. Our case also puts forward the use of topical ivermectin as a possibly effective CLM treatment approach as our patient was successfully treated with 1 month of an ivermectin 1% cream applied locally twice daily.

Background: Oestrogen dermatitis is a rare disorder characterised by cyclical eruptions in association with a woman's menstrual cycle., Methods: A 43-year-old woman with an 8-year history of cyclical inguinal dermatitis, with a negative patch test, was tested with intradermal progesterone and oestrogen., Results: Intradermal testing was positive for oestrogen only., Conclusion: In a female patient with cyclical dermatitis, it is important to consider oestrogen or progesterone dermatitis in the differential diagnosis.

Juvenile xanthogranuloma (JXG) is the most frequent form of non-Langerhans cell histiocytosis. We present a case of giant congenital JXG in a 7-week-old boy, who had a firm and incompressible lesion, measuring 3 × 4 cm in diameter, on his right flank. The clinical appearance of the lesion and the ultrasound results suggested a vascular tumor, such as a hemangioma. Histology confirmed a JXG, although there was an absence of Touton cells, which are usually pathognomonic of JXG. In light of these findings, it would be important to include JXG in the differential diagnosis of congenital tumours, particularly vascular lesions.

Background: Eosinophilic fasciitis is a rare sclerosing syndrome with a poorly understood etiology., Objective: We report a case of eosinophilic fasciitis in a 40-year-old man undergoing treatment with natalizumab for multiple sclerosis. Natalizumab is a selective adhesion molecule inhibitor that prevents interaction of leukocytes with endothelial cells. Peripheral blood eosinophilia has been described under treatment with natalizumab, but we herein report the first case to our knowledge of eosinophilic fasciitis as a possible complication of this medication.